Cargando…

HPV infection in oral cancer, our experience: prevalence, clinical implications, and current vaccination program in Spain

BACKGROUND: Oral cancer is the 11th most common type of cancer in the world, with established major risk factors as tobacco and alcohol, and recently included high-risk human papillomavirus types 16 and 18. HPV types 16 and 18 are the etiologic agents of cervical cancers and a proportion of orophary...

Descripción completa

Detalles Bibliográficos
Autores principales: Aragón-Niño, Íñigo, Cuesta-Urquía, Carolina, González-Martín-Moro, Javier, Morán-Soto, María-José, Pozo-Kreilinger, José-Juan, Pampín-Martinez, Marta-María, del Castillo-Pardo-de Vera, José-Luis, Cebrián-Carretero, José-Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medicina Oral S.L. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382160/
https://www.ncbi.nlm.nih.gov/pubmed/37519322
http://dx.doi.org/10.4317/jced.60514
_version_ 1785080623825682432
author Aragón-Niño, Íñigo
Cuesta-Urquía, Carolina
González-Martín-Moro, Javier
Morán-Soto, María-José
Pozo-Kreilinger, José-Juan
Pampín-Martinez, Marta-María
del Castillo-Pardo-de Vera, José-Luis
Cebrián-Carretero, José-Luis
author_facet Aragón-Niño, Íñigo
Cuesta-Urquía, Carolina
González-Martín-Moro, Javier
Morán-Soto, María-José
Pozo-Kreilinger, José-Juan
Pampín-Martinez, Marta-María
del Castillo-Pardo-de Vera, José-Luis
Cebrián-Carretero, José-Luis
author_sort Aragón-Niño, Íñigo
collection PubMed
description BACKGROUND: Oral cancer is the 11th most common type of cancer in the world, with established major risk factors as tobacco and alcohol, and recently included high-risk human papillomavirus types 16 and 18. HPV types 16 and 18 are the etiologic agents of cervical cancers and a proportion of oropharyngeal cancers. However, the picture of HPV and the clinical implications of oral cancers are not clear with most reports combining oral cancer data with head and neck cancers. It has been confirmed as a favorable prognostic factor in oropharyngeal cancer. However, the prognostic value of HPV in oral squamous cell carcinoma is still unclear. MATERIAL AND METHODS: The main objective of this article is to present the evidence encountered following a bibliographical review of recent publications specifically related to oral cancer and its differences from oropharyngeal cancer. The secondary goals are to present the findings of a five-year retrospective observational study of the prevalence of HPV infection in oral cancer patients treated by the Oral and Maxillofacial Surgery Department at La Paz University Hospital (Madrid, Spain), and finally, we to evaluate and compare our country’s HPV prevention program in comparison to other European countries. RESULTS: According to the review of the literature, HPV positive oral squamous cell carcinoma is associated with significantly decreased overall survival and distant control. Bibliographic review suggest HPV infection can be used as a negative prognostic factor in oral squamous cell carcinoma. CONCLUSIONS: As regards diagnostic testing for HPV, it should be extended to as many cases of oral cavity squamous cell carcinoma as possible, especially in those with risk factors. The current vaccination program in Spain does not have adequate coverage and is significantly under the level of other European Union countries; it should be expanded and catch-up strategies should be included. Key words:HPV, OSSC, Papillomavirus, oral carcinoma, prevention.
format Online
Article
Text
id pubmed-10382160
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Medicina Oral S.L.
record_format MEDLINE/PubMed
spelling pubmed-103821602023-07-29 HPV infection in oral cancer, our experience: prevalence, clinical implications, and current vaccination program in Spain Aragón-Niño, Íñigo Cuesta-Urquía, Carolina González-Martín-Moro, Javier Morán-Soto, María-José Pozo-Kreilinger, José-Juan Pampín-Martinez, Marta-María del Castillo-Pardo-de Vera, José-Luis Cebrián-Carretero, José-Luis J Clin Exp Dent Review BACKGROUND: Oral cancer is the 11th most common type of cancer in the world, with established major risk factors as tobacco and alcohol, and recently included high-risk human papillomavirus types 16 and 18. HPV types 16 and 18 are the etiologic agents of cervical cancers and a proportion of oropharyngeal cancers. However, the picture of HPV and the clinical implications of oral cancers are not clear with most reports combining oral cancer data with head and neck cancers. It has been confirmed as a favorable prognostic factor in oropharyngeal cancer. However, the prognostic value of HPV in oral squamous cell carcinoma is still unclear. MATERIAL AND METHODS: The main objective of this article is to present the evidence encountered following a bibliographical review of recent publications specifically related to oral cancer and its differences from oropharyngeal cancer. The secondary goals are to present the findings of a five-year retrospective observational study of the prevalence of HPV infection in oral cancer patients treated by the Oral and Maxillofacial Surgery Department at La Paz University Hospital (Madrid, Spain), and finally, we to evaluate and compare our country’s HPV prevention program in comparison to other European countries. RESULTS: According to the review of the literature, HPV positive oral squamous cell carcinoma is associated with significantly decreased overall survival and distant control. Bibliographic review suggest HPV infection can be used as a negative prognostic factor in oral squamous cell carcinoma. CONCLUSIONS: As regards diagnostic testing for HPV, it should be extended to as many cases of oral cavity squamous cell carcinoma as possible, especially in those with risk factors. The current vaccination program in Spain does not have adequate coverage and is significantly under the level of other European Union countries; it should be expanded and catch-up strategies should be included. Key words:HPV, OSSC, Papillomavirus, oral carcinoma, prevention. Medicina Oral S.L. 2023-07-01 /pmc/articles/PMC10382160/ /pubmed/37519322 http://dx.doi.org/10.4317/jced.60514 Text en Copyright: © 2023 Medicina Oral S.L. https://creativecommons.org/licenses/by/2.5/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Aragón-Niño, Íñigo
Cuesta-Urquía, Carolina
González-Martín-Moro, Javier
Morán-Soto, María-José
Pozo-Kreilinger, José-Juan
Pampín-Martinez, Marta-María
del Castillo-Pardo-de Vera, José-Luis
Cebrián-Carretero, José-Luis
HPV infection in oral cancer, our experience: prevalence, clinical implications, and current vaccination program in Spain
title HPV infection in oral cancer, our experience: prevalence, clinical implications, and current vaccination program in Spain
title_full HPV infection in oral cancer, our experience: prevalence, clinical implications, and current vaccination program in Spain
title_fullStr HPV infection in oral cancer, our experience: prevalence, clinical implications, and current vaccination program in Spain
title_full_unstemmed HPV infection in oral cancer, our experience: prevalence, clinical implications, and current vaccination program in Spain
title_short HPV infection in oral cancer, our experience: prevalence, clinical implications, and current vaccination program in Spain
title_sort hpv infection in oral cancer, our experience: prevalence, clinical implications, and current vaccination program in spain
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382160/
https://www.ncbi.nlm.nih.gov/pubmed/37519322
http://dx.doi.org/10.4317/jced.60514
work_keys_str_mv AT aragonninoinigo hpvinfectioninoralcancerourexperienceprevalenceclinicalimplicationsandcurrentvaccinationprograminspain
AT cuestaurquiacarolina hpvinfectioninoralcancerourexperienceprevalenceclinicalimplicationsandcurrentvaccinationprograminspain
AT gonzalezmartinmorojavier hpvinfectioninoralcancerourexperienceprevalenceclinicalimplicationsandcurrentvaccinationprograminspain
AT moransotomariajose hpvinfectioninoralcancerourexperienceprevalenceclinicalimplicationsandcurrentvaccinationprograminspain
AT pozokreilingerjosejuan hpvinfectioninoralcancerourexperienceprevalenceclinicalimplicationsandcurrentvaccinationprograminspain
AT pampinmartinezmartamaria hpvinfectioninoralcancerourexperienceprevalenceclinicalimplicationsandcurrentvaccinationprograminspain
AT delcastillopardodeverajoseluis hpvinfectioninoralcancerourexperienceprevalenceclinicalimplicationsandcurrentvaccinationprograminspain
AT cebriancarreterojoseluis hpvinfectioninoralcancerourexperienceprevalenceclinicalimplicationsandcurrentvaccinationprograminspain